Core Insights - Anteris Technologies Global Corp. announced the presentation of one-year clinical outcomes for the DurAVR Transcatheter Heart Valve (THV) at the TCT 2025 conference, highlighting its commitment to innovative heart solutions [1][2]. Company Overview - Anteris Technologies is a global structural heart company focused on designing, developing, and commercializing advanced medical devices aimed at restoring healthy heart function. The company has a significant presence in both Australia and Minneapolis, USA [4]. - The DurAVR THV is the company's lead product, designed in collaboration with leading interventional cardiologists and cardiac surgeons to treat aortic stenosis, a serious condition caused by the narrowing of the aortic valve [5]. Product Details - The DurAVR THV is the first biomimetic valve, engineered to replicate the performance of a healthy human aortic valve and normal aortic blood flow. It is constructed from a single piece of molded ADAPT tissue, which is FDA-cleared and has been used in over 55,000 patients globally [5]. - The DurAVR THV System includes the DurAVR valve, ADAPT tissue, and the balloon-expandable ComASUR Delivery System [5]. Clinical Trials - The clinical outcomes for the DurAVR THV have been encouraging, with over 100 patients implanted. These outcomes will be further assessed in the global pivotal PARADIGM Trial, which is a prospective randomized controlled trial evaluating the safety and effectiveness of the DurAVR THV against existing transcatheter aortic valve replacements [3].
Anteris Technologies Announces One-Year Clinical Outcomes for DurAVR® THV to be Presented at TCT® 2025